HROC419 T0 M2 Cells

The HROC (Hansestadt Rostock Colorectal cancer) cell line panel comprises patient-derived colorectal cancer models developed from primary tumor tissue and/or matched metastatic lesions. These cell lines are frequently accompanied by corresponding patient-derived xenografts (PDXs) and organoids, enabling integrative modeling of colorectal cancer (CRC) in both in vitro and in vivo systems. HROC models preserve critical clinical and molecular diversity found in colorectal cancer, including variations in microsatellite instability (MSI vs. MSS) and key genetic drivers such as mutations in APC, KRAS, BRAF, PIK3CA, and TP53. Cultured as adherent epithelial monolayers and typically used at low passage numbers, HROC lines maintain phenotypic and genomic fidelity to their patient tumors, supporting translational relevance in drug and biomarker research.

The nomenclature system for HROC cell lines provides detailed metadata on origin and experimental history. For example, “Tu” identifies cell lines derived from primary tumors, “Met” from metastatic lesions, while “T#” and “M#” indicate the number of PDX transfers and the specific mouse host, respectively. This systematic naming allows for easy tracking of matched sets, such as primary-metastasis pairs or in vitro-in vivo derivatives. These matched models support studies on clonal evolution, metastasis, therapy resistance, and pharmacokinetic behavior—including transporter expression and barrier integrity relevant for drug absorption. Cell lines undergo routine authentication (e.g., STR profiling) and are tested regularly for mycoplasma contamination. Characterization data for numerous HROC models are publicly available in Cellosaurus and in peer-reviewed publications.

HROC cell lines are particularly valuable for subtype-stratified drug screening, biomarker discovery across MSI-H and MSS tumors, and mechanistic studies involving primary vs. metastatic disease. When paired with PDXs and/or organoids, they provide a robust platform for preclinical evaluation, including drug sensitivity testing and modeling of tumor-stroma or immune interactions. Due to their comprehensive annotation and clinical relevance, HROC models are suitable for both basic and translational research in colorectal cancer.